Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemother...
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 24
- Registration Number
- NCT05775900
- Locations
- 🇨🇳
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Short-course Radiotherapy Combined With Chemotherapy and Pd-1 Inhibitor for Locally Advanced Colon Cancer(TORCH-C)
- Conditions
- Interventions
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 120
- Registration Number
- NCT05732493
Serplulimab Combined with CAPEOX + Celecoxib As Neoadjuvant Treatment for Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 50
- Registration Number
- NCT05731726
- Locations
- 🇨🇳
Second Affiliated Hospital School of Medicine Zhejiang University, Hangzhou, Zhejiang, China
Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Liaoning Tumor Hospital & Institute
- Target Recruit Count
- 100
- Registration Number
- NCT05720559
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment
- Conditions
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-02-08
- Target Recruit Count
- 500
- Registration Number
- NCT05717764
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT05702229
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT05700084
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
- Conditions
- Interventions
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Sonya Reid
- Target Recruit Count
- 64
- Registration Number
- NCT05693766
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-12-13
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Binhui Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT05648006
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)
- Conditions
- Interventions
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1514
- Registration Number
- NCT05633654
- Locations
- 🇺🇸
Alabama Oncology, Birmingham, Alabama, United States
🇺🇸Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸Northwestern Medicine, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.